Developer docs
API playgroundTry for free, no card

Search company profiles

Ordaos Bio

Full company profile

uuid0000a57

Namestring
Ordaos Bio
Legal namestring
Ordaos, Inc.
Websiteurl
ordaos.bio
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ordaos Bio is a privately held, AI-native biotechnology company that designs de novo mini-proteins for therapeutic drug discovery. The company's core product is the miniPRO™ platform — a class of mini-proteins (40–160 amino acids, roughly 20x smaller than monoclonal antibodies) engineered to combine antibody-like target specificity with improved thermostability, solubility, manufacturability, and the ability to penetrate disease microenvironments including tumors and the blood-brain barrier. Mini-proteins are generated by the Ordaos Design Engine, a proprietary multitask meta-learning model that combines generative AI and reinforcement learning on public and proprietary datasets. The engine generates, appraises, and ranks billions of candidate sequences and hundreds of thousands of structures against a client-defined molecular target product profile (mTPP), iterating via a continuous in silico-to-in vitro learning loop with the company's wet-lab at JLABS@NYC. Notable technical outputs include de novo HER2 binders produced within weeks and single-domain VHH antibodies against SARS-CoV-2 S1 with picomolar to sub-nanomolar binding affinity.

Ordaos operates as a B2B drug-design partner for pharmaceutical and biotechnology companies, monetizing through joint development agreements, research collaborations, and milestone-based programs rather than selling a standalone product. Its named partners are predominantly small-to-mid biotechs focused on difficult-to-drug oncology indications: NonExomics (three rare cancer targets, Sept 2022), Yatiri Bio (two AML targets, Dec 2022), FatiAbGen (pancreatic and ovarian cancer antibody optimization, Feb 2023), and a three-way collaboration with Vyant Bio and Cellaria (biomarker-specific small proteins, April 2021). The company also runs an internal pipeline focused on overlooked patient populations in triple-negative breast cancer, esophageal cancer, and AML. Go-to-market relies on direct enterprise partnerships supplemented by JLABS@NYC (Johnson & Johnson Innovation) infrastructure, AWS Generative AI Accelerator compute credits, and CRO relationships for productionized protein production.

The company is Delaware-incorporated (Ordaos, Inc.), headquartered in New York, NY, and has raised approximately $15M+ cumulatively across a 2020 pre-seed round, a $5M seed in August 2022 led by Middleland Capital's VTC Ventures, a $1.8M convertible note in September 2023, a $3.1M exempt securities offering in September 2024, and a smaller filing in April 2025. The leadership team combines pharma R&D experience (ex-GSK, ex-Rockefeller) with applied ML/AI pedigree (ex-DARPA, Pfizer, BOSCH), and the company maintains an active conference presence at BIO, PEGS, JPM Healthcare, and PMWC.

Short descriptiontext

Ordaos Bio is a private, AI-native biotechnology company that uses a proprietary generative AI Design Engine to design de novo mini-proteins (miniPRO™) for pharmaceutical and biotech partners, targeting difficult-to-drug oncology and rare disease indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI protein design, mini-protein therapeutics, de novo drug discovery, generative AI biologics, antibody alternatives
Industry3 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Driven Protein Drug Discovery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Partner Collaboration Agreements
TypeProfessional Services
Description

Ordaos generates revenue through partnerships with pharma and biotech companies for drug design and discovery services, including joint development agreements and research collaborations to create novel therapeutics against specific targets.

ordaos.bio
2Joint Development Agreements
TypeProfessional Services
Description

Collaborative agreements where Ordaos uses its Design Engine to create protein candidates while partners provide target identification and preclinical validation capabilities, with milestone-based development.

ordaos.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1miniPRO™
Description

A class of mini-proteins (40-160 amino acids) that provide antibody-like power and performance while being more configurable, stable, and easier to manufacture. 20x smaller than traditional monoclonal antibodies.

ordaos.bio
Core offering1 text field

Ordaos Bio partners with pharmaceutical and biotechnology companies to design novel, de novo mini-proteins (miniPRO™, 40-160 amino acids) using its proprietary AI-driven Design Engine. The company offers both custom mini-protein design against client-specified molecular target product profiles and optimization of existing antibody programs, delivering therapeutic candidates intended to be smaller, more stable, and easier to manufacture than traditional monoclonal antibodies. Services are delivered through joint development agreements and research collaborations targeting difficult-to-drug diseases and overlooked patient populations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • miniPRO™ proteins are 93% smaller than standard of care HER2-targeting treatments
+4 more records
Product overview1 text field

Ordaos Bio is a human-enabled, machine-driven drug design company offering a unified platform centered on two core offerings: the miniPRO™ mini-protein product line and the Ordaōs Design Engine technology platform. The Design Engine serves as the foundational technology that generates de novo mini-proteins, while miniPRO™ represents the actual therapeutic mini-protein products created using the platform. Together, these offerings enable pharma and biotech partners to design and deliver safer, more effective therapeutics in a fraction of the time required by traditional discovery methods.

Product and service3 records
1miniPRO™
CategoryTherapeutic proteins / biologics modality
Description

A class of de novo designed mini-proteins (40-160 amino acids) that deliver antibody-like binding and specificity while being more configurable, thermostable, soluble, and easier to manufacture than traditional monoclonal antibodies. Designed to penetrate disease microenvironments and address targets difficult for full-size antibodies, intended for pharmaceutical and biotechnology partners developing therapeutics in oncology and rare disease.

2Ordaōs Design Engine
CategoryAI drug design platform / drug discovery service
Description

A multitask meta-learning platform that uses generative AI and reinforcement learning, trained on public and proprietary biological datasets, to design de novo mini-proteins from amino acids. Generates, appraises, and ranks billions of protein sequences and hundreds of thousands of protein structures against client-specified molecular target product profiles (mTPPs), optimizing simultaneously across structure, binding specificity and affinity, solubility, stability, immunogenicity, and developability. Delivered as a service to pharmaceutical and biotechnology partners.

3Custom Mini-Protein Design and Antibody Optimization Partnerships
CategoryDrug discovery collaboration / co-development service
Description

Engagement-based drug design services delivered through joint development agreements and research collaborations with pharma and biotech partners. Each engagement scopes a set of molecular targets or antibody optimization objectives, with Ordaos applying the Design Engine and miniPRO™ approach to generate, validate in vitro, and advance de novo protein candidates. Active engagements span difficult-to-drug oncology indications (triple-negative breast, pancreatic, ovarian, AML, esophageal) and rare cancers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-24
Description

Residency at JLABS@NYC providing lab space, industry connections, entrepreneurial programs, and collaboration opportunities. The residency supports R&D optimization, enables in-house wet lab capabilities, and provides access to Johnson & Johnson's resources and expertise.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-09
Description

Selected for inaugural AWS Generative AI Accelerator cohort, receiving up to $300,000 in AWS credits, training, mentorship, technical guidance, and introductions to industry leaders and potential investors. AWS provides cloud infrastructure support for Ordaos' generative AI and protein design operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-22
Description

Collaboration to optimize monoclonal antibodies for challenging oncology conditions including pancreatic and ovarian cancer. Ordaos uses its in silico Design Engine to enhance safety and efficacy of FatiAbGen's existing monoclonal antibodies while FatiAbGen develops optimized antibodies in preclinical studies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-19
Description

Joint development agreement to create novel therapeutics for two novel targets in Acute Myeloid Leukemia (AML). Yatiri Bio identifies cell surface therapeutic targets using its proteomics platform while Ordaos creates de novo protein candidates using its Design Engine and conducts in vitro validation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-28
Description

Research collaboration to develop miniPROs for three specific difficult-to-target rare cancers. Ordaos uses its Design Engine to generate and rank novel miniPRO candidates while NonExomics conducts preclinical certification to demonstrate commercial value. NonExomics leverages AI and proteogenomics to identify novel disease-associated biomarkers from non-conventional protein-coding regions.

6Vyant Bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-22
Description

Three-way collaboration to design and qualify biomarker-specific small protein therapeutics. Vyant Bio provides preclinical development expertise and regulatory readiness while Ordaos generates in silico protein sequences and Cellaria provides patient-specific cell models for testing.

ordaos.bio
7Cellaria
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-22
Description

Three-way collaboration providing patient-specific cell models and in vitro tumor models for therapeutic evaluation. Cellaria's models are directly linked to patient disease states enabling genomic, proteomic, and combinatorial analysis for target validation.

ordaos.bio
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Flagship-backed generative AI platform for de novo protein therapeutics. Directly comparable to Ordaos's Design Engine approach of designing novel proteins in silico rather than discovering them, with a similar pharma partnership GTM and a focus on hard-to-drug targets.

TypeDirect peer
Description

AI-driven protein design company serving biotech and pharma partners to engineer novel biologics, including enzymes and therapeutic proteins. Closely parallels Ordaos's B2B partnership model and generative protein design methodology.

TypeDirect peer
Description

Uses large language models trained on biological sequences to design novel proteins de novo, including CRISPR-Cas variants and antibodies. Highly comparable technology stack and 'design from scratch' philosophy.

TypeDirect peer
Description

AI-powered generative protein design platform with wet-lab validation for therapeutic antibodies and beyond. Comparable in combining in silico design with high-throughput wet-lab iteration, and also partners with pharma on de novo biologics.

5Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction to therapeutic design. Represents the well-capitalized incumbent version of Ordaos's vision, with pharma partnerships (Eli Lilly, Novartis) and broader scope.

TypeBroad incumbent
Description

Public computational chemistry and biology platform serving pharma with molecular simulation, including protein design and predictive modeling. A larger, established player whose broader platform overlaps with Ordaos's in silico protein engineering capabilities.

TypeBroad incumbent
Description

Public AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Operates at much larger scale than Ordaos but pursues adjacent AI-for-biologics-discovery territory.

TypeDirect peer
Description

AI/ML-driven antibody design platform integrating wet-lab high-throughput characterization with generative models. Closely comparable to Ordaos in targeting antibody/mini-protein therapeutics through an integrated design-validate loop.

TypeEmerging player
Description

Early-stage AI protein engineering company focused on automated wet-lab validation of designed proteins. Overlaps with Ordaos in generative protein design but at smaller scale and more focused on tooling/infrastructure.

TypeDirect peer
Description

Clinical-stage developer of designed ankyrin repeat proteins (DARPins), which are 40-160 amino acid mini-proteins functionally analogous to Ordaos's miniPROs. Most direct modality competitor, with validated clinical assets and pharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ordaos Bio

AI-Driven Protein Drug Discoveryordaos.bio

Ordaos Bio is a private, AI-native biotechnology company that uses a proprietary generative AI Design Engine to design de novo mini-proteins (miniPRO™) for pharmaceutical and biotech partners, targeting difficult-to-drug oncology and rare disease indications.

What Ordaos Bio does

Ordaos Bio is a privately held, AI-native biotechnology company that designs de novo mini-proteins for therapeutic drug discovery. The company's core product is the miniPRO™ platform — a class of mini-proteins (40–160 amino acids, roughly 20x smaller than monoclonal antibodies) engineered to combine antibody-like target specificity with improved thermostability, solubility, manufacturability, and the ability to penetrate disease microenvironments including tumors and the blood-brain barrier. Mini-proteins are generated by the Ordaos Design Engine, a proprietary multitask meta-learning model that combines generative AI and reinforcement learning on public and proprietary datasets. The engine generates, appraises, and ranks billions of candidate sequences and hundreds of thousands of structures against a client-defined molecular target product profile (mTPP), iterating via a continuous in silico-to-in vitro learning loop with the company's wet-lab at JLABS@NYC. Notable technical outputs include de novo HER2 binders produced within weeks and single-domain VHH antibodies against SARS-CoV-2 S1 with picomolar to sub-nanomolar binding affinity.

Ordaos operates as a B2B drug-design partner for pharmaceutical and biotechnology companies, monetizing through joint development agreements, research collaborations, and milestone-based programs rather than selling a standalone product. Its named partners are predominantly small-to-mid biotechs focused on difficult-to-drug oncology indications: NonExomics (three rare cancer targets, Sept 2022), Yatiri Bio (two AML targets, Dec 2022), FatiAbGen (pancreatic and ovarian cancer antibody optimization, Feb 2023), and a three-way collaboration with Vyant Bio and Cellaria (biomarker-specific small proteins, April 2021). The company also runs an internal pipeline focused on overlooked patient populations in triple-negative breast cancer, esophageal cancer, and AML. Go-to-market relies on direct enterprise partnerships supplemented by JLABS@NYC (Johnson & Johnson Innovation) infrastructure, AWS Generative AI Accelerator compute credits, and CRO relationships for productionized protein production.

The company is Delaware-incorporated (Ordaos, Inc.), headquartered in New York, NY, and has raised approximately $15M+ cumulatively across a 2020 pre-seed round, a $5M seed in August 2022 led by Middleland Capital's VTC Ventures, a $1.8M convertible note in September 2023, a $3.1M exempt securities offering in September 2024, and a smaller filing in April 2025. The leadership team combines pharma R&D experience (ex-GSK, ex-Rockefeller) with applied ML/AI pedigree (ex-DARPA, Pfizer, BOSCH), and the company maintains an active conference presence at BIO, PEGS, JPM Healthcare, and PMWC.

Ordaos Bio firmographics

Firmographics
Name
Ordaos Bio
Legal name
Ordaos, Inc.
Website
https://ordaos.bio
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Ordaos Bio is a private, AI-native biotechnology company that uses a proprietary generative AI Design Engine to design de novo mini-proteins (miniPRO™) for pharmaceutical and biotech partners, targeting difficult-to-drug oncology and rare disease indications.
Ownership category
akta.pro rank

Ordaos Bio industry classification

Industry
Product category
AI-Driven Protein Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI protein design
  • Mini-protein therapeutics
  • De novo drug discovery
  • Generative AI biologics
  • Antibody alternatives

Where Ordaos Bio is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ordaos Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partner Collaboration Agreements: Ordaos generates revenue through partnerships with pharma and biotech companies for drug design and discovery services, including joint development agreements and research collaborations to create novel therapeutics against specific targets.
  2. Joint Development Agreements: Collaborative agreements where Ordaos uses its Design Engine to create protein candidates while partners provide target identification and preclinical validation capabilities, with milestone-based development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Ordaos Bio product offering

Product offering

Core offering

Ordaos Bio partners with pharmaceutical and biotechnology companies to design novel, de novo mini-proteins (miniPRO™, 40-160 amino acids) using its proprietary AI-driven Design Engine. The company offers both custom mini-protein design against client-specified molecular target product profiles and optimization of existing antibody programs, delivering therapeutic candidates intended to be smaller, more stable, and easier to manufacture than traditional monoclonal antibodies. Services are delivered through joint development agreements and research collaborations targeting difficult-to-drug diseases and overlooked patient populations.

Product overview

Ordaos Bio is a human-enabled, machine-driven drug design company offering a unified platform centered on two core offerings: the miniPRO™ mini-protein product line and the Ordaōs Design Engine technology platform. The Design Engine serves as the foundational technology that generates de novo mini-proteins, while miniPRO™ represents the actual therapeutic mini-protein products created using the platform. Together, these offerings enable pharma and biotech partners to design and deliver safer, more effective therapeutics in a fraction of the time required by traditional discovery methods.

Differentiator

Problem solved

Functional benefit

Brands

  • miniPRO™: A class of mini-proteins (40-160 amino acids) that provide antibody-like power and performance while being more configurable, stable, and easier to manufacture. 20x smaller than traditional monoclonal antibodies.

Products and services

  • miniPRO™ A class of de novo designed mini-proteins (40-160 amino acids) that deliver antibody-like binding and specificity while being more configurable, thermostable, soluble, and easier to manufacture than traditional monoclonal antibodies. Designed to penetrate disease microenvironments and address targets difficult for full-size antibodies, intended for pharmaceutical and biotechnology partners developing therapeutics in oncology and rare disease.
  • Ordaōs Design Engine A multitask meta-learning platform that uses generative AI and reinforcement learning, trained on public and proprietary biological datasets, to design de novo mini-proteins from amino acids. Generates, appraises, and ranks billions of protein sequences and hundreds of thousands of protein structures against client-specified molecular target product profiles (mTPPs), optimizing simultaneously across structure, binding specificity and affinity, solubility, stability, immunogenicity, and developability. Delivered as a service to pharmaceutical and biotechnology partners.
  • Custom Mini-Protein Design and Antibody Optimization Partnerships Engagement-based drug design services delivered through joint development agreements and research collaborations with pharma and biotech partners. Each engagement scopes a set of molecular targets or antibody optimization objectives, with Ordaos applying the Design Engine and miniPRO™ approach to generate, validate in vitro, and advance de novo protein candidates. Active engagements span difficult-to-drug oncology indications (triple-negative breast, pancreatic, ovarian, AML, esophageal) and rare cancers.

Quantifiable outcome

  • miniPRO™ proteins are 93% smaller than standard of care HER2-targeting treatments
  • +4 more outcomes

Companies that use Ordaos Bio

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Ordaos Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Ordaos Bio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Johnson & Johnson Innovation - JLABScoreStrategic or Co-development Partner · 24 August 2023Residency at JLABS@NYC providing lab space, industry connections, entrepreneurial programs, and collaboration opportunities. The residency supports R&D optimization, enables in-house wet lab capabilities, and provides access to Johnson & Johnson's resources and expertise.
  • AWS (Amazon Web Services)coreTechnology or Integration · 9 June 2023Selected for inaugural AWS Generative AI Accelerator cohort, receiving up to $300,000 in AWS credits, training, mentorship, technical guidance, and introductions to industry leaders and potential investors. AWS provides cloud infrastructure support for Ordaos' generative AI and protein design operations.
  • FatiAbGencoreStrategic or Co-development Partner · 22 February 2023Collaboration to optimize monoclonal antibodies for challenging oncology conditions including pancreatic and ovarian cancer. Ordaos uses its in silico Design Engine to enhance safety and efficacy of FatiAbGen's existing monoclonal antibodies while FatiAbGen develops optimized antibodies in preclinical studies.
  • Yatiri BiocoreStrategic or Co-development Partner · 19 December 2022Joint development agreement to create novel therapeutics for two novel targets in Acute Myeloid Leukemia (AML). Yatiri Bio identifies cell surface therapeutic targets using its proteomics platform while Ordaos creates de novo protein candidates using its Design Engine and conducts in vitro validation.
  • NonExomicscoreStrategic or Co-development Partner · 28 September 2022Research collaboration to develop miniPROs for three specific difficult-to-target rare cancers. Ordaos uses its Design Engine to generate and rank novel miniPRO candidates while NonExomics conducts preclinical certification to demonstrate commercial value. NonExomics leverages AI and proteogenomics to identify novel disease-associated biomarkers from non-conventional protein-coding regions.
  • Vyant BiocoreStrategic or Co-development Partner · 22 April 2021Three-way collaboration to design and qualify biomarker-specific small protein therapeutics. Vyant Bio provides preclinical development expertise and regulatory readiness while Ordaos generates in silico protein sequences and Cellaria provides patient-specific cell models for testing.
  • CellariacoreStrategic or Co-development Partner · 22 April 2021Three-way collaboration providing patient-specific cell models and in vitro tumor models for therapeutic evaluation. Cellaria's models are directly linked to patient disease states enabling genomic, proteomic, and combinatorial analysis for target validation.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Ordaos Bio competitors and assessment

Company assessment

Direct peers

  • Generate Biomedicines: Flagship-backed generative AI platform for de novo protein therapeutics. Directly comparable to Ordaos's Design Engine approach of designing novel proteins in silico rather than discovering them, with a similar pharma partnership GTM and a focus on hard-to-drug targets.
  • Cradle Bio: AI-driven protein design company serving biotech and pharma partners to engineer novel biologics, including enzymes and therapeutic proteins. Closely parallels Ordaos's B2B partnership model and generative protein design methodology.
  • Profluent Bio: Uses large language models trained on biological sequences to design novel proteins de novo, including CRISPR-Cas variants and antibodies. Highly comparable technology stack and 'design from scratch' philosophy.
  • Absci: AI-powered generative protein design platform with wet-lab validation for therapeutic antibodies and beyond. Comparable in combining in silico design with high-throughput wet-lab iteration, and also partners with pharma on de novo biologics.
  • BigHat Biosciences: AI/ML-driven antibody design platform integrating wet-lab high-throughput characterization with generative models. Closely comparable to Ordaos in targeting antibody/mini-protein therapeutics through an integrated design-validate loop.
  • Molecular Partners: Clinical-stage developer of designed ankyrin repeat proteins (DARPins), which are 40-160 amino acid mini-proteins functionally analogous to Ordaos's miniPROs. Most direct modality competitor, with validated clinical assets and pharma partnerships.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction to therapeutic design. Represents the well-capitalized incumbent version of Ordaos's vision, with pharma partnerships (Eli Lilly, Novartis) and broader scope.
  • Schrödinger: Public computational chemistry and biology platform serving pharma with molecular simulation, including protein design and predictive modeling. A larger, established player whose broader platform overlaps with Ordaos's in silico protein engineering capabilities.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Operates at much larger scale than Ordaos but pursues adjacent AI-for-biologics-discovery territory.

Emerging players

  • Adaptyv Bio: Early-stage AI protein engineering company focused on automated wet-lab validation of designed proteins. Overlaps with Ordaos in generative protein design but at smaller scale and more focused on tooling/infrastructure.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Ordaos Bio social profiles

Digital presence

Ordaos Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ordaos Bio leadership team

Management profile

Number of profiles

Profiles5 records

Ordaos Bio funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ordaos Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ordaos Bio

What does Ordaos Bio do?

Ordaos Bio partners with pharmaceutical and biotechnology companies to design novel, de novo mini-proteins (miniPRO™, 40-160 amino acids) using its proprietary AI-driven Design Engine. The company offers both custom mini-protein design against client-specified molecular target product profiles and optimization of existing antibody programs, delivering therapeutic candidates intended to be smaller, more stable, and easier to manufacture than traditional monoclonal antibodies. Services are delivered through joint development agreements and research collaborations targeting difficult-to-drug diseases and overlooked patient populations.

Is Ordaos Bio a public or private company?

Ordaos Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ordaos Bio founded?

Ordaos Bio was founded in 2021. It employs 11 to 50 people.

Where is Ordaos Bio based?

Ordaos Bio is headquartered in New York, United States, in the North America region.

How does Ordaos Bio make money?

Two revenue lines are on record. Partner Collaboration Agreements are the primary driver. The others are joint Development Agreements.

Who are Ordaos Bio's main competitors?

Direct peers on record are Generate Biomedicines, Cradle Bio, Profluent Bio, Absci, BigHat Biosciences and Molecular Partners. Broad incumbents are Isomorphic Labs, Schrödinger and Recursion Pharmaceuticals. Adaptyv Bio is listed as an emerging player.

Does Ordaos Bio have an API?

No public API is recorded for Ordaos Bio.

What industry is Ordaos Bio in?

Ordaos Bio's product category is AI-Driven Protein Drug Discovery. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DOrdaos, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b), with total offering amounts reaching $4 million. The filing indicates that $3,104,999 has been sold to five investors as of late August 2024, with the remainder still available. The company is based in New York and operates within the biotechnology sector.MorningstarOrdaōs Acquires the Carterra®LSA® Platform to Further Speed and Optimize Its Machine-Driven Drug Design SystemOrdaōs acquired Carterra's LSA platform to accelerate its machine-driven drug design system. The platform enables analysis of up to 150,000 interactions in a single assay and supports AI/ML workflows. The acquisition aims to speed and optimize drug discovery for difficult-to-treat diseases.SecSEC FORM DOrdaos, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt securities offering under Regulation D Rule 506(b). The company is raising up to $5 million in convertible debt, having already sold $1.8 million to four investors since March 2023. This regulatory filing serves as formal notification of the private capital raise rather than a market-moving commercial event.Labiotech.euOrdaōs and Yatiri Bio to tackle AMLOrdaōs and Yatiri Bio announced a joint development agreement to create new therapeutics for acute myeloid leukemia (AML) targets. Yatiri Bio will identify two cell surface targets using patient proteomics, while Ordaōs will design mini-protein candidates and validate them in vitro. The partners plan to jointly develop leads for an IND submission.BioSpaceOrdaōs Announces Appointment of Ziwei Liang, PhD to Role of Chief Science OfficerOrdaōs appointed co-founder Ziwei Liang, PhD, as Chief Science Officer to lead drug discovery and AI-driven protein design. She previously led antibody discovery and oncology cell therapy programs at GlaxoSmithKline and the Tri-Institutional Therapeutic Discovery Institute. The role will drive the company's miniPRO™ protein development strategy.BioSpaceOrdaōs/NonExomics Deal Shines Light on Novel Mini-ProteinsOrdaōs and NonExomics announced a research pact to develop miniPROs for three rare cancers. Ordaōs will use its Design Engine to identify candidates, while NonExomics will conduct preclinical studies. The miniPROs are 40-160 amino acid proteins, larger than peptides, designed to be inserted into tumor microenvironments.SecSEC FORM DOrdaos, Inc. filed a Form D with the U.S. Securities and Exchange Commission on June 15, 2022, announcing an exempt securities offering under Rule 506(b). The company reported raising a total of $10,742,419 from 10 investors, with no remaining amount to be sold.